If there are rare reports of acquired fusions at progression under EGFR-TKIs, the incidence of such alterations seems to be more important than in naïve NSCLC patients, but with unusual partners of fusions and/or breakpoints. This evidence concerns the gene EGFR and non-small cell lung carcinoma.